Abstract
Neurologic dysfunction is a well-recognized adverse effect of cancer therapeutics. The most common manifestations include peripheral neuropathy and encephalopathy. Often, symptoms resolve or improve upon removal of the offending agent; therefore, it is essential that clinicians recognize the symptoms and signs of injury. Occasionally, symptoms persist or develop after discontinuation of medication and may culminate in disability and diminished quality of life. As our understanding of neurotoxicity improves, medications with less potential for injury may be developed. In addition, potential antidotes to prevent or reverse injury may emerge. This review focuses on the clinical features, mechanisms, and possible therapeutics of the neurotoxicity of chemotherapy. In particular, oxaliplatin, thalidomide, methotrexate, ifosfamide, cytarabine, amifostine, acetyl-L-carnitine, methylene blue, cytokines, and neurotrophins are discussed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Leonard GD, Wright MA, Quinn MG, et al.: Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 2005, 5:116.
Cersosimo RJ: Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 2005, 39:128–135.
Lehky TJ, Leonard GD, Wilson RH, et al.: Oxaliplatininduced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004, 29:387–392. A clinical and electrophysiologic study of the acute neuropathic syndrome in oxaliplatin-treated patients.
Wilson RH, Lehky T, Thomas RR, et al.: Acute oxaliplatininduced peripheral nerve hyperexcitability. J Clin Oncol 2002, 20:1767–1774.
Grolleau F, Gamelin L, Boisdron-Celle M, et al.: A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001, 85:2293–2297.
Webster RG, Brain KL, Wilson RH, et al.: Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol 2005, 146:1027–1039.
Krishnan AV, Goldstein D, Friedlander M, Kiernan MC: Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005, 32:51–60.
Jamieson SM, Liu J, Connor B, McKeage MJ: Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother Pharmacol 2005, 56:391–399.
Gamelin L, Boisdron-Celle M, Delva R, et al.: Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004, 10:4055–4061. A large retrospective study of oxaliplatin-exposed patients treated with or without calcium and magnesium infusions as a neuroprohylactic measure.
Lersch C, Schmelz R, Eckel F, et al.: Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Cancer 2002, 2:54–58.
Penz M, Kornek GV, Raderer M, et al.: Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol 2001, 12:421–422.
Isoardo G, Bergui M, Durelli L, et al.: Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurol Scand 2004, 109:188–193.
Giannini F, Volpi N, Rossi S, et al.: Thalidomide-induced neuropathy: a ganglionopathy? Neurology 2003, 60:877–878.
Steurer M, Spizzo G, Mitterer M, Gastl G: Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program. Onkologie 2004, 27:150–154.
Cavaletti G, Beronio A, Reni L, et al.: Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 2004, 62:2291–2293. A retrospective study of patients treated with thalidomide who underwent both clinical and neurophysiologic assessments; it may explain some of the inconsistencies regarding the relationship between dose and neuropathy.
Briani C, Zara G, Rondinone R, et al.: Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology 2004, 62:2288–2290.
Tosi P, Zamagni E, Cellini C, et al.: Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005, 74:212–216.
Bastuji-Garin S, Ochonisky S, Bouche P, et al.: Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol 2002, 119:1020–1026.
Koukourakis MI, Simopoulos C, Minopoulos G, et al.: Amifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous route. Clin Cancer Res 2003, 9:3288–3293.
Verstappen CC, Postma TJ, Geldof AA, Heimans JJ: Amifostine protects against chemotherapy-induced neurotoxicity: an in vitro investigation. Anticancer Res 2004, 24:2337–2341.
Hussain AE, Blakley BW, Nicolas M, Balderston J: Assessment of the protective effects of amifostine against cisplatin-induced toxicity. J Otolaryngol 2003, 32:294–297.
Hilpert F, Stahle A, Tome O, et al.: Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer 2005, 13:797–805.
Lorusso D, Ferrandina G, Greggi S, et al.: Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 2003, 14:1086–1093.
Openshaw H, Beamon K, Synold TW, et al.: Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res 2004, 10:461–467.
Glover D, Ibrahim J, Kirkwood J, et al.: Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). Melanoma Res 2003, 13:619–626.
Moore DH, Donnelly J, McGuire WP, et al.: Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. J Clin Oncol 2003, 21:4207–4213.
Leong SS, Tan EH, Fong KW, et al.: Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-smallcell lung cancer. J Clin Oncol 2003, 21:1767–1774.
Rudolph S, Ridwelski K, Kuhn R, Lippert H: Randomised trial with or without amifostine to reduce neurotoxicity side effects under chemotherapy with oxaliplatin, 5-FU. Ann Oncol 2000 11(Suppl 4):154.
De Santis S, Pace A, Bove L, et al.: Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res 2000, 6:90–95.
Cavaletti G, Bogliun G, Marzorati L, et al.: Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol 2004, 15:1439–1442.
Cavaletti G, Pezzoni G, Pisano C, et al.: Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor. Neurosci Lett 2002, 322:103–106.
Aloe L, Manni L, Properzi F, et al.: Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by cisplatin: behavioral, structural and biochemical analysis. Auton Neurosci 2000, 86:84–93.
Tredici G, Braga M, Nicolini G, et al.: Effect of recombinant human nerve growth factor on cisplatin neurotoxicity in rats. Exp Neurol 1999, 159:551–558.
Boyle FM, Beatson C, Monk R, et al.: The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin. Cancer Chemother Pharmacol 2001, 48:429–434.
Davis ID, Kiers L, MacGregor L, et al.: A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res 2005, 11:1890–1898.
Pisano C, Pratesi G, Laccabue D, et al.: Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 2003, 9:5756–5767.
Maestri A, De Pasquale Ceratti A, Cundari S, et al.: A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 2005, 91:135–138.
Bianchi G, Vitali G, Caraceni A, et al.: Symptomatic and neurophysiological responses of paclitaxel- or cisplatininduced neuropathy to oral acetyl-l-carnitine. Eur J Cancer 2005, 41:1746–1750.
Weigel R, Senn P, Weis J, Krauss JK: Severe complications after intrathecal methotrexate (MTX) for treatment of primary central nervous system lymphoma (PCNSL). Clin Neurol Neurosurg 2004, 106:82–87.
Drachtman RA, Cole PD, Golden CB, et al.: Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr Hematol Oncol 2002, 19:319–327.
Atra A, Pinkerton CR, Bouffet E, et al.: Acute neurotoxicity in children with advanced stage B-non-Hodgkin’s lymphoma and B-acute lymphoblastic leukaemia treated with the United Kingdom children cancer study group 9002/9003 protocols. Eur J Cancer 2004, 40:1346–1350.
Brock S, Jennings HR: Fatal acute encephalomyelitis after a single dose of intrathecal methotrexate. Pharmacotherapy 2004, 24:673–676.
Lee ST, Kim M: Diffusion-weighted MRIs in an acute leukoencephalopathy following intrathecal chemotherapy. Neurology 2004, 62:832–833.
Rollins N, Winick N, Bash R, Booth T: Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. Am J Neuroradiol 2004, 25:1688–1695.
Bay A, Oner AF, Etlik O, et al.: Myelopathy due to intrathecal chemotherapy: report of six cases. J Pediatr Hematol Oncol 2005, 27:270–272.
Oka M, Terae S, Kobayashi R, et al.: MRI in methotrexaterelated leukoencephalopathy: Disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy. Neuroradiology 2003, 45:493–497.
Kuker W, Bader P, Herrlinger U, et al.: Transient encephalopathy after intrathekal methotrexate chemotherapy: diffusion-weighted MRI. J Neuro-oncol 2005, 73:47–49.
Fisher MJ, Khademian ZP, Simon EM, et al.: Diffusionweighted MR imaging of early methotrexate-related neurotoxicity in children. Am J Neuroradiol 2005, 26:1686–1689.
Gowan GM, Herrington JD, Simonetta AB: Methotrexate-induced toxic leukoencephalopathy. Pharmacotherapy 2002, 22:1183–1187.
Lai R, Abrey LE, Rosenblum MK, DeAngelis LM: Treatmentinduced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 2004, 62:451–456.
Chu WC, Chik KW, Chan YL, et al.: White matter and cerebral metabolite changes in children undergoing treatment for acute lymphoblastic leukemia: longitudinal study with MR imaging and 1H MR spectroscopy. Radiology 2003, 229:659–669.
Reddick WE, Glass JO, Helton KJ, et al.: A quantitative MR imaging assessment of leukoencephalopathy in children treated for acute lymphoblastic leukemia without irradiation. AJNR Am J Neuroradiol 2005, 26:2371–2377. Prospective quantitative MRI study of children with ALL treated on a single protocol without cranial irradiation.
Montour-Proulx I, Kuehn SM, Keene DL, et al.: Cognitive changes in children treated for acute lymphoblastic leukemia with chemotherapy only according to the Pediatric Oncology Group 9605 protocol. J Child Neurol 2005, 20:129–133.
Kingma A, van Dommelen RI, Mooyaart EL, et al.: Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only. J Pediatr 2001, 139:413–420.
Hill DE, Ciesielski KT, Hart BL, Jung RE: MRI morphometric and neuropsychological correlates of long-term memory in survivors of childhood leukemia. Pediatr Blood Cancer 2004, 42:611–617.
Harder H, Holtel H, Bromberg JE, et al.: Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 2004, 62:544–547.
Correa DD, DeAngelis LM, Shi W, et al.: Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 2004, 62:548–555. A cross-sectional, neuropsychologic, and radiographic study of patients with primary central nervous system lymphoma in remission following treatment with high-dose intravenous methotrexate with or without cranial irradiation.
Neuwelt EA, Guastadisegni PE, Varallyay P, Doolittle ND: Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. Am J Neuroradiol 2005, 26:258–265. A longitudinal study of patients with primary central nervous system lymphoma achieving a complete response following enhanced delivery of methotrexate-based chemotherapy.
McAllister LD, Doolittle ND, Guastadisegni PE, et al.: Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000, 46:51–60 ; discussion 60–61.
Hoang-Xuan K, Taillandier L, Chinot O, et al.: Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003, 21:2726–2731.
Fliessbach K, Urbach H, Helmstaedter C, et al.: Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch Neurol 2003, 60:563–568.
Batchelor T, Carson K, O’Neill A, et al.: Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003, 21:1044–1049.
Paakko E, Harila-Saari A, Vanionpaa L, et al.: White matter changes on MRI during treatment in children with acute lymphoblastic leukemia: correlation with neuropsychological findings. Med Pediatr Oncol 2000, 35:456–461.
Kishi S, Griener J, Cheng C, et al.: Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003, 21:3084–3091.
Valik D, Sterba J, Bajciova V, Demlova R: Severe encephalopathy induced by the first but not the second course of high-dose methotrexate mirrored by plasma homocysteine elevations and preceded by extreme differences in pretreatment plasma folate. Oncology 2005, 69:269–272.
Chiusolo P, Reddiconto G, Casorelli I, et al.: Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 2002, 13:1915–1918.
Linnebank M, Pels H, Kleczar N, et al.: MTX-induced white matter changes are associated with polymorphisms of methionine metabolism. Neurology 2005, 64:912–913. A retrospective report of a possible association between certain polymorphisms influencing methionine metabolism and leukoencephalopathy. This is a representative paper of the emerging field of pharmacogenomics.
Peyriere H, Poiree M, Cociglio M, et al.: Reversal of neurologic disturbances related to high-dose methotrexate by aminophylline. Med Pediatr Oncol 2001, 36:662–664.
Kerbusch T, de Kraker J, Keizer HJ, et al.: Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinetics 2001, 40:41–62.
Rieger C, Fiegl M, Tischer J, et al.: Incidence and severity of ifosfamide-induced encephalopathy. Anticancer Drugs 2004, 15:347–350.
Nicolao P, Giometto B: Neurological toxicity of ifosfamide. Oncology 2003, 65(Suppl 2):11–16.
Zielinska E, Zubowska M, Misiura K: Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children. J Pediatr Hematol Oncol 2005, 27:582–589.
Park IS, Lee HJ, Lee YS, et al.: Ifosfamide-induced encephalopathy with or without using methylene blue. Int J Gynecol Cancer 2005, 15:807–810.
Pelgrims J, De Vos F, Van den Brande J, et al.: Methylene blue in the treatment and prevention of ifosfamideinduced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000, 82:291–294.
Raj AB, Bertolone SJ, Jaffe N: Methylene blue reversal of ifosfamide-related encephalopathy. J Pediatr Hematol Oncol 2004, 26:116.
Turner AR, Duong CD, Good DJ: Methylene blue for the treatment and prophylaxis of ifosfamide-induced encephalopathy. Clin Oncol (R Coll Radiol) 2003, 15:435–439.
Courtney MJ, Coffey ET: The mechanism of Ara-C-induced apoptosis of differentiating cerebellar granule neurons. Eur J Neurosci 1999, 11:1073–1084.
Geller HM, Cheng KY, Goldsmith NK, et al.: Oxidative stress mediates neuronal DNA damage and apoptosis in response to cytosine arabinoside. J Neurochem 2001, 78:265–275.
Ahlemeyer B, Kolker S, Zhu Y, et al.: Cytosine arabinofuranoside-induced activation of astrocytes increases the susceptibility of neurons to glutamate due to the release of soluble factors. Neurochem Int 2003, 42:567–581.
Brezden CB, Phillips KA, Abdolell M, et al.: Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000, 18:2695–2701.
van Dam FS, Schagen SB, Muller MJ, et al.: Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998, 90:210–218.
Ahles TA, Saykin AJ, Furstenberg CT, et al.: Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002, 20:485–493.
Tchen N, Juffs HG, Downie FP, et al.: Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003, 21:4175–4183.
Wefel JS, Lenzi R, Theriault RL, et al.: The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004, 100:2292–2299. A prospective longitudinal study of breast cancer patients without central nervous system disease treated with chemotherapy.
Schagen SB, Hamburger HL, Muller MJ, et al.: Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neuro-oncol 2001, 51:159–165.
Jenkins V, Shilling V, Fallowfield L, et al.: Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 2004, 13:61–66.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cavaliere, R., Schiff, D. Neurologic toxicities of cancer therapies. Curr Neurol Neurosci Rep 6, 218–226 (2006). https://doi.org/10.1007/s11910-006-0009-8
Issue Date:
DOI: https://doi.org/10.1007/s11910-006-0009-8